drugset
Drugs / GNSC-001
last change Apr 2025 re-read 3 minutes ago

GNSC-001

Gene therapy (AAV / viral vector)

Developed for
osteoarthritis, knee
Investigated by
California Institute for Regenerative Medicine (CIRM) · Genascence Corporation

Trials 1

today NCT05835895 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05835895 Jun 2023 → Apr 2025 overdue osteoarthritis, knee Genascence Corporation Active not recruiting No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2024-01-03 Genascence Corporation Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA) genascence.com ↗
2023-10-24 Genascence Corporation Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress genascence.com ↗
2022-05-17 Genascence Corporation Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting genascence.com ↗
2022-05-05 Genascence Corporation Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis genascence.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GNSC-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05835895 ↗
Modality Gene therapy (AAV / viral vector) “adeno-associated virus (AAV) gene therapy (GNSC-001)” NCT05835895 ↗
Route Other “intra-articular injection” NCT05835895 ↗